Undifferentiated Shock & Vasopressors

A. Master Therapeutic & Escalation Table (Vasopressors, Inotropes & Adjuncts)

B. Crash-Cart Mixing & Drip-Titration Box (Arithmetically Verified)

CRASH-CART PREPARATION, PUSH-DOSE PRESSORS & EXTRAVASATION RESCUE RECIPES

1. Push-Dose Phenylephrine (100 mcg/mL) — Pure α₁ Rescue for Peri-Intubation Vasoplegia + Tachycardia:

• Preparation: Take a 100 mL bag of 0.9% Normal Saline and inject 1 mL of Phenylephrine (10 mg/mL vial) into the bag. Mix thoroughly and draw up into a labeled 10 mL syringe. (Alternative Double-Dilution in Syringe: Dilute 1 mL [10 mg] of Phenylephrine into 9 mL NS [= 1 mg/mL]; then take 1 mL [1 mg] of that solution and dilute into another 9 mL NS syringe).
• Final Concentration: 1,000 mcg ÷ 10 mL = 100 mcg/mL.
• Bedside Execution: Administer 0.5 to 2 mL (50–200 mcg) IV push every 2–5 minutes (onset 45 s, duration 15 min).

2. Push-Dose Epinephrine (10 mcg/mL) — Inopressor Rescue for Bradycardic / Cardiogenic / Undifferentiated Crash:

• Preparation: Into a 10 mL syringe containing 9 mL of 0.9% Normal Saline, draw 1 mL of Crash-Cart Cardiac Epinephrine (0.1 mg/mL [1:10,000] prefilled syringe).
• Final Concentration: 100 mcg ÷ 10 mL = 10 mcg/mL.
• Bedside Execution: Administer 0.5 to 2 mL (5–20 mcg) IV push every 2–5 minutes.

3. Norepinephrine Standard Infusion (16 mcg/mL) — First-Line Shock Drip:

• Preparation: Add 4 mg (1 ampule of 4 mg/4 mL) of Norepinephrine to 250 mL of D5W or NS → Final Concentration = 16 mcg/mL.
• Pump Rate Conversion (for an 80 kg Adult):
  • 0.05 mcg/kg/min (4 mcg/min): 240 mcg/hr ÷ 16 mcg/mL = 15 mL/hr.
  • 0.10 mcg/kg/min (8 mcg/min): 480 mcg/hr ÷ 16 mcg/mL = 30 mL/hr.
  • 0.25 mcg/kg/min (20 mcg/min): 1,200 mcg/hr ÷ 16 mcg/mL = 75 mL/hr.
  • 0.50 mcg/kg/min (40 mcg/min): 2,400 mcg/hr ÷ 16 mcg/mL = 150 mL/hr.

4. Vasopressin Infusion (0.4 Units/mL) — Catecholamine-Sparing Second-Line Drip:

• Preparation: Add 40 Units (2 vials of 20 Units/mL) of Vasopressin to 100 mL of NS or D5W → Final Concentration = 0.4 Units/mL.
• Pump Rate Execution (Fixed Non-Weight-Based Rate):
  • 0.03 Units/min (1.8 Units/hr): 1.8 ÷ 0.4 = 4.5 mL/hr.
  • 0.04 Units/min (2.4 Units/hr): 2.4 ÷ 0.4 = 6.0 mL/hr.

5. Dobutamine Infusion (1,000 mcg/mL) — Inotropic Support:

• Preparation: Add 250 mg (1 vial of 250 mg/20 mL) of Dobutamine to 250 mL of D5W or NS → Final Concentration = 1,000 mcg/mL (1 mg/mL).
• Pump Rate Conversion (for an 80 kg Adult):
  • 5 mcg/kg/min (400 mcg/min): 24,000 mcg/hr ÷ 1,000 mcg/mL = 24 mL/hr.
  • 10 mcg/kg/min (800 mcg/min): 48 mL/hr.

6. Peripheral Vasopressor Extravasation Antidote (“The Rule of 5s” Phentolamine Rescue):

• Immediate Action: DO NOT remove the extravasated IV catheter yet! Stop the infusion, disconnect tubing, and aspirate 3–5 mL of blood/drug back through the existing catheter.
• Antidote Preparation & Execution: Dilute 5 mg to 10 mg of Phentolamine (competitive α₁-antagonist) in 10 mL of 0.9% Normal Saline (0.5–1.0 mg/mL). Inject 2 mL through the indwelling catheter before removing it, then use a 25G–27G needle to infiltrate the remaining 8 mL subcutaneously in a circular clock-face pattern around the blanched ischemic perimeter. Apply warm compresses and topical 2% Nitroglycerin ointment (1-inch strip) if Phentolamine is unavailable.

C. The Refractory Crashing Patient (Minute 15–30 Salvage & Resource-Limited Bailouts)

When a patient remains in profound hypotension (MAP < 55–60 mmHg) despite Norepinephrine ≥ 0.5 mcg/kg/min, Vasopressin 0.03 Units/min, and Hydrocortisone 100 mg IV:

1. Correct the “Four Hidden Metabolic Saboteurs of Vasopressors”:
   • Severe Ionized Hypocalcemia (iCa²⁺ < 0.9 mmol/L): Vascular smooth muscle contraction (α₁-IP₃-calmodulin-MLCK) and myocardial excitation-contraction coupling depend entirely on Ca²⁺. Citrate in blood transfusions and sepsis-induced parathyroid resistance drop iCa²⁺. Administer Calcium Chloride 10% 1 g (10 mL) IV over 5 minutes (often restores MAP by +15–20 mmHg immediately).
   • Profound Acidemia (pH < 7.15) with Acute Kidney Injury [BICAR-ICU Trial]: At pH < 7.15, α₁ receptors desensitize and vascular KATP channels hyperpolarize. If accompanied by Stage 2–3 AKI, infuse Isotonic 4.2% or Hypertonic 8.4% Sodium Bicarbonate (or 150 mEq NaHCO₃ in 1 L D5W) targeting pH 7.20–7.30.
   • Occult Adrenal Crisis / Myxedema Coma: Ensure Hydrocortisone 100 mg IV bolus has been given; consider Levothyroxine 200 mcg IV if hypothermic/bradycardic shock is unresponsive.
   • Occult Mechanical Obstruction / Abdominal Compartment Syndrome (ACS): Repeat RUSH POCUS for delayed tension pneumothorax (post-intubation!), pericardial tamponade, or bladder pressure > 20 mmHg (ACS).
2. Third-Line Non-Adrenergic Vasopressor Salvage (Angiotensin II & Methylene Blue):
   • Angiotensin II (Giapreza) [ATHOS-3 Trial]: Agonizes AT₁ receptors (Gq-coupled) to vasoconstrict both afferent and efferent arterioles (with greater efferent constriction → preserves GFR). Start at 20 ng/kg/min IV, titrate every 5 min up to 80 ng/kg/min during the first 3 hours, then maintain ≤ 40 ng/kg/min (co-administer DVT prophylaxis).
   • Methylene Blue (Nitric Oxide / cGMP Scavenger): Directly inhibits inducible Nitric Oxide Synthase (iNOS) and soluble Guanylyl Cyclase (sGC) in refractory vasoplegia. Administer 1.5–2.0 mg/kg IV over 20–30 minutes (diluted in 100 mL D5W), followed by 0.25–0.5 mg/kg/hr. Contraindications: G6PD deficiency (hemolysis) and serotonergic drugs/SSRIs (potent MAO-A inhibitor → precipitates fatal Serotonin Syndrome).
   • Hydroxocobalamin (Cyanokit): 5 g IV over 15 minutes acts as a direct intravascular nitric oxide (NO) and hydrogen sulfide (H₂S) scavenger when Methylene Blue is contraindicated.
3. Mechanical Circulatory Support (VA-ECMO / Impella): If refractory shock is driven by pump failure (Cardiac Index < 1.8 L/min/m², LVOT-VTI < 10 cm, Lactate > 8 mmol/L), activate the Shock Team for Impella CP or VA-ECMO before multiorgan necrosis becomes irreversible.

D. Vulnerable Physiological Extremes Matrix (Pregnancy, Pediatrics & Geriatrics)

⚠ E. “NEVER DO THIS & WHY” (Pathophysiological & Mechanical Counter-Examples)

5 LETHAL SHOCK RESUSCITATION ERRORS & THEIR EXACT MECHANISM OF HARM

1. NEVER delay Norepinephrine initiation while waiting to place a Central Venous Catheter (CVC) [CENSER & CLOVERS Trials]. Why (Duration of Hypotension Directly Multiplies Organ Necrosis & Peripheral Infusions Are Safe): Every 10-minute delay in correcting MAP < 65 mmHg increases acute kidney injury, myocardial injury, and 28-day mortality by 5– 7%. Large prospective studies and RCTs (CENSER Trial, CLOVERS Trial) prove that infusing Norepinephrine (16 mcg/mL) through a well-positioned proximal peripheral IV (18G–16G in or proximal to the antecubital fossa) for up to 24 hours has a local extravasation rate of < 2–3%, with zero cases of tissue necrosis when monitored every 2 hours [5,12].
2. NEVER administer Pure α₁-Agonists (Phenylephrine) as monotherapy in Cardiogenic Shock or Right Ventricular (RV) Failure. Why (Afterload Mismatch & Reflex Bradycardia): A failing left ventricle sits on a flattened Frank-Starling curve where Stroke Volume is inversely proportional to afterload (Laplace’s Law: Wall Stress σ = [P × r] / 2h). Phenylephrine spikes arterial resistance (↑ P) without providing any β₁ inotropic support, clamping down on LV outflow and triggering baroreceptor-mediated vagal bradycardia—crashing Cardiac Output (CO = HR × SV). Furthermore, in RV failure (Massive PE or RV MI), Phenylephrine constricts the pulmonary arterial bed via α₁ receptors, worsening pulmonary vascular resistance (PVR) and acute cor pulmonale; use Norepinephrine + Vasopressin instead (Vasopressin has zero V₁a receptors in the pulmonary arteries) [9].
3. NEVER perform Rapid Sequence Intubation (RSI) in an unresuscitated shock patient (Shock Index ≥ 0.9) without prior Push-Dose / Continuous Vasopressor support and pre-induction hemodynamic optimization. Why (Loss of Endogenous Sympathetic Tone & Positive-Pressure Preload Collapse): Induction agents (especially Propofol and high-dose Midazolam/Fentanyl) abruptly abolish the patient’s compensatory sympathetic surge, causing immediate venodilation (↓ Pmsf). Simultaneously, switching from negative-pressure spontaneous breathing to positive-pressure mechanical ventilation elevates intrathoracic pressure (↑ PRA), collapsing venous return to the right atrium and precipitating immediate post-intubation PEA arrest. Always resuscitate before you intubate: start a Norepinephrine drip, have Push-Dose Epinephrine (10 mcg/mL) in hand, and use hemodynamically neutral induction (Ketamine 0.5–1.0 mg/kg IV or Etomidate 0.15–0.3 mg/kg IV).
4. NEVER use Dopamine as the first-line vasopressor in Septic or Cardiogenic Shock [SOAP II Trial]. Why (Arrhythmogenesis, Hypothalamic-Pituitary Suppression & Increased Mortality): In the landmark SOAP II randomized trial (N = 1,679), Dopamine caused twice as many arrhythmias as Norepinephrine (24.1% vs. 12.4%, p < 0.001) and significantly increased 28-day mortality in the cardiogenic shock subgroup (p = 0.03) [4].
5. NEVER infuse large volumes of 0.9% Normal Saline (> 2 L) in undifferentiated or septic shock [SMART Trial]. Why (Hyperchloremic Metabolic Acidosis & Tubuloglomerular Feedback Vasoconstriction): 0.9% Normal Saline contains a supraphysiologic chloride concentration of 154 mmol/L (vs. normal plasma [Cl⁻] = 98–106 mmol/L). Under Stewart’s physicochemical acid-base model, flooding the extracellular space with Cl⁻ narrows the Strong Ion Difference (SID), causing severe non-anion-gap hyperchloremic acidosis. Worse, high luminal [Cl⁻] reaching the macula densa triggers adenosine-mediated constriction of the renal afferent arteriole, dropping GFR and increasing Major Adverse Kidney Events (SMART Trial) [3].

A. Disposition & ICU Escalation Criteria

• Immediate Operating Theater / Interventional Radiology / Cath Lab (Direct Source Control):
  • Hemorrhagic Shock: Ruptured Abdominal Aortic Aneurysm (AAA), ruptured ectopic pregnancy, penetrating thoracoabdominal trauma, or unstable pelvic ring fracture (IR embolization / preperitoneal packing).
  • Obstructive / Cardiogenic Shock: Acute STEMI/OMI with cardiogenic shock (CULPRIT-SHOCK strategy: culprit-lesion-only PCI), high-risk massive PE with contraindication to systemic thrombolysis (surgical/catheter thrombectomy), or acute mechanical MI complication.
  • Septic Source Control: Necrotizing fasciitis, Fournier gangrene, perforated viscus, or obstructive pyelonephritis/ascending cholangitis (must achieve decompression within ≤ 6 hours of presentation) [1].
• Medical / Surgical Intensive Care Unit (MICU / SICU) Admission: All patients requiring continuous vasopressor or inotropic support, invasive arterial pressure monitoring, mechanical ventilation, or presenting with persistent hyperlactatemia (Lactate > 2.0 mmol/L) despite initial fluid resuscitation.
• High-Dependency Unit (HDU) / Step-Down Admission: Patients with resolved transient hypovolemic or early distributive shock whose MAP remains ≥ 65 mmHg off vasopressors for > 4 hours, with normalized CRT (≤ 3 s), downward-trending lactate (< 2.0 mmol/L), and urine output ≥ 0.5 mL/kg/hr.

B. Program Director’s Quality KPIs, Accreditation (JCI / CBAHI / GAHAR / Ada’a) & M&M Audit Points

• Time to RUSH POCUS Completion in Undifferentiated Hypotension (SBP < 90 mmHg or SI ≥ 1.0): ≤ 10 minutes from triage/resuscitation bay arrival, with images archived and documented in the medical record [2].
• Time to Initial Lactate Result & Repeat Lactate: Initial point-of-care lactate within ≤ 15 minutes; mandatory repeat lactate ordered within 2 to 4 hours for any initial value > 2.0 mmol/L (CMS SEP-1 / Saudi MoH Ada’a Core KPI) [1].
• Time to Vasopressor Initiation in Fluid-Refractory Hypotension (MAP < 65 mmHg): ≤ 30 minutes from recognition via proximal peripheral IV while preparing central venous access [1,5].
• Peripheral Vasopressor Safety Protocol Compliance (JCI / CBAHI Medication Safety Standard): 100% documentation of IV site proximal to the wrist (18G–16G), positive blood return check, q2h visual/palpation skin inspection, and bedside availability of Phentolamine 5–10 mg rescue kit [1,12].
• M&M Audit Red Flag (“Post-Intubation Cardiac Arrest in Shock”): Every peri-intubation cardiac arrest occurring within 30 minutes of ED RSI must undergo Root Cause Analysis (RCA) auditing whether the Shock Index (≥ 0.9) was calculated pre-RSI and whether vasopressors were running prior to induction push.

C. Structured Clinical SBAR Handover (ED Consultant to Medical ICU Consultant)

A. OSCE & Oral Board Examiner Rubric (Topic 1.2)

To achieve a Pass / Distinction rating on an Undifferentiated Shock Resuscitation OSCE Station, the candidate must execute and verbalize the following 4 critical milestones:

1. Immediate RUSH POCUS Categorization (< 2 Minutes): Verbalizes and performs the HI-MAP scan (Pump, Tank, Pipes) to classify the shock phenotype (Hypovolemic, Cardiogenic, Obstructive, Distributive, or Mixed) before ordering unguided high-volume fluid boluses [2].
2. Physiologically Sound Fluid & Early Peripheral Vasopressor Execution: Selects Balanced Crystalloids (Lactated Ringer’s or Plasma-Lyte) over 0.9% Normal Saline [3], assesses dynamic fluid responsiveness (Passive Leg Raise + LVOT-VTI or PPV), and initiates Norepinephrine immediately via a proximal peripheral IV without delaying for central venous access [1,5,12].
3. Receptor-Matched Second-Line Vasopressor / Inotrope Escalation: Adds Vasopressin (0.03 Units/min) when Norepinephrine reaches 0.25–0.5 mcg/kg/min in vasodilatory shock (plus Hydrocortisone 50 mg IV q6h) [1,6,7], OR adds Dobutamine (2–20 mcg/kg/min) if POCUS/ScvO₂/ΔPv₋aCO₂ demonstrates myocardial depression [1,11].
4. Microcirculatory Endpoint Titration & Peri-Intubation Safety: Titrates resuscitation to MAP ≥ 65 mmHg, Capillary Refill Time ≤ 3 seconds (ANDROMEDA-SHOCK), and serial lactate clearance [8], and explicitly stabilizes hemodynamics with vasopressors prior to attempting any endotracheal intubation.

B. 2 Board-Style Clinical Vignette MCQs (SCFHS / MRCEM / ABEM Level)

Vignette 1: A 71-year-old male with a history of hypertension and benign prostatic hyperplasia presents to the Emergency Department with fever, rigors, and confusion following an indwelling urinary catheter change 24 hours ago. His initial vital signs are: BP 74/34 mmHg (MAP 47 mmHg), HR 124 bpm, RR 26/min, SpO₂ 96% on room air, and temperature 39.2°C. His capillary refill time is 5 seconds, and point-of-care arterial lactate is 4.9 mmol/L. Bedside RUSH POCUS reveals a hyperdynamic left ventricle, an IVC diameter of 1.2 cm with > 50% collapse, and bilateral A-lines on lung ultrasound. After receiving 1,500 mL of Lactated Ringer’s and broad-spectrum IV antibiotics, he is started on a Norepinephrine infusion via a right internal jugular central line. Over the next 2 hours, his Norepinephrine requirement escalates to 0.45 mcg/kg/min to maintain a MAP of 62 mmHg. Repeat arterial blood gas shows pH 7.12, PaCO₂ 32 mmHg, HCO₃⁻ 10 mEq/L, and ionized Ca²⁺ 1.18 mmol/L. Repeat POCUS confirms preserved LV contractility (LVEF 65%, LVOT-VTI 21 cm). Which of the following is the most appropriate next pharmacologic intervention to restore vascular tone in this acidemic patient?

• A. Discontinue Norepinephrine and initiate a Dopamine infusion at 20 mcg/kg/min.
• B. Add a continuous infusion of Vasopressin at 0.03 Units/min and administer Hydrocortisone 50 mg IV.
• C. Add a Dobutamine infusion at 10 mcg/kg/min to augment cardiac output.
• D. Add a Phenylephrine infusion at 200 mcg/min and administer 3,000 mL of 0.9% Normal Saline.

Correct Answer: B.

Mechanism & Explanation: In severe septic shock with profound acidemia (pH 7.12) and high-dose Norepinephrine (≥ 0.25–0.5 mcg/kg/min), α₁-adrenergic receptors undergo phosphorylation-induced desensitization, internalization, and protonation, while vascular smooth muscle KATP channels open—causing catecholamine-refractory vasoplegia. Adding Vasopressin (0.03 Units/min) bypasses the adrenergic receptor completely by activating V₁a (Gq-coupled) receptors and directly inhibiting KATP channels, remaining fully active in severe acidemia (VASST and VANISH trials) [1,6,9]. Co-administering stress-dose Hydrocortisone (50 mg IV q6h) upregulates nuclear transcription of α₁ receptors and inhibits iNOS (APROCCHSS trial) [1,7].

Why Distractors Fail: A is contraindicated because the SOAP II trial proved Dopamine doubles lethal arrhythmias and is inferior to Norepinephrine [4]. C is incorrect because RUSH POCUS confirms a hyperdynamic LV (LVEF 65%, normal LVOT-VTI 21 cm); adding Dobutamine (β₁/β₂ inodilator) without low cardiac output will worsen vasodilation (β₂) and hypotension. D is incorrect because Phenylephrine acts on the exact same saturated/desensitized α₁ receptor as Norepinephrine, and 3 L of 0.9% Normal Saline will worsen acidemia via hyperchloremia (SMART trial) [3].

Vignette 2: A 58-year-old female presents to the Emergency Department 3 days after a viral prodrome with progressive orthopnea, cold extremities, and lethargy. Her vital signs are: BP 76/54 mmHg (MAP 61 mmHg), HR 118 bpm, RR 28/min, and SpO₂ 90% on 6 L/min nasal cannula. Bedside RUSH POCUS demonstrates global biventricular hypokinesis with an estimated LVEF of 15–20%, an LVOT-VTI of 9 cm, a dilated non-collapsing IVC (2.4 cm), diffuse bilateral pulmonary B-lines, and no pericardial effusion. Central venous blood gas from a newly placed internal jugular line reveals ScvO₂ 48%, a veno-arterial CO₂ gap (ΔPv₋aCO₂) of 11 mmHg, and a serum lactate of 5.4 mmol/L. She is started on Norepinephrine at 0.08 mcg/kg/min, which raises her MAP to 67 mmHg, but her extremities remain mottled and LVOT-VTI decreases to 8 cm. Her home medications include Carvedilol 25 mg twice daily for chronic heart failure, and her serum creatinine is 1.0 mg/dL (normal renal function). Which of the following is the best pharmacologic strategy to improve her stroke volume and tissue perfusion?

• A. Escalate Norepinephrine to 0.4 mcg/kg/min to target a MAP of 85 mmHg.
• B. Administer a 30 mL/kg (2,000 mL) bolus of Lactated Ringer’s to optimize LV preload.
• C. Initiate a Milrinone continuous infusion at 0.25 mcg/kg/min (without a loading bolus) while maintaining Norepinephrine to support MAP ≥ 65 mmHg.
• D. Administer Metoprolol 5 mg IV push to slow the heart rate and improve diastolic filling time.

Correct Answer: C.

Mechanism & Explanation: This patient is in severe Cardiogenic Shock (likely acute fulminant myocarditis or decompensated HFrEF) characterized by a critically low stroke volume (LVOT-VTI 8–9 cm), low ScvO₂ (48%), wide veno-arterial CO₂ gap (11 mmHg), and pulmonary congestion (diffuse B-lines + plethoric IVC). Because she is on high-dose chronic Carvedilol (a competitive β₁/β₂/α₁ blocker), β₁-adrenergic agonists like Dobutamine face competitive receptor antagonism. Milrinone inhibits intracellular Phosphodiesterase-3 (PDE-3) distal to the blocked β₁ receptor, preventing cAMP breakdown to increase myocardial contractility (inotropy) and reduce LV afterload (inodilation), thereby increasing LVOT-VTI and stroke volume [11]. Omitting the loading bolus prevents precipitous hypotension, and maintaining low-dose Norepinephrine preserves coronary perfusion pressure (MAP ≥ 65 mmHg).

Why Distractors Fail: A worsens cardiogenic shock because excessive α₁ vasoconstriction increases LV afterload (wall stress), causing the failing ventricle’s stroke volume (LVOT-VTI) to drop even further. B will precipitate fatal cardiogenic pulmonary edema in a patient already exhibiting diffuse B-lines and a 2.4 cm IVC. D is lethal in decompensated cardiogenic shock; negative inotropes (β-blockers) abolish compensatory contractility and precipitate PEA arrest.